Corvus Pharmaceuticals CRVS Change in Lease Liabilities
Change in Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's change in lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's change in lease liabilities?
- Corvus Pharmaceuticals (CRVS) reported change in lease liabilities of -$103K in Q1 2026.
- How has Corvus Pharmaceuticals's change in lease liabilities changed year-over-year?
- Corvus Pharmaceuticals's change in lease liabilities decreased by 432.3% year-over-year, from $31K to -$103K.
- What is the long-term trend for Corvus Pharmaceuticals's change in lease liabilities?
- Over 2 years (2022 to 2025), Corvus Pharmaceuticals's change in lease liabilities has grown at a -57.9% compound annual growth rate (CAGR), from -$1.05M to -$185K.
- What does change in lease liabilities mean?
- Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.